Zymeworks Inc. (ZYME) 株式分析

企業概要

Zymeworks Inc. is a biotechnology enterprise dedicated to the development and commercialization of biotherapeutics designed to address complex medical conditions, specifically cancer, inflammation, and autoimmune diseases. The company operates within the Healthcare sector, more specifically within the Biotechnology industry, an environment characterized by high research and development expenditures and significant regulatory oversight required for product approval. As of the latest reporting period, the company maintains a market capitalization of $1.98 billion and employs a workforce of 264 individuals to execute its strategic platforms. With an annual revenue of $105.97 million, these financial figures indicate that Zymeworks occupies a mid-cap position in the biotechnology landscape, suggesting it has moved beyond the initial discovery phase but still faces the substantial capital demands typical of pre-commercialization or early-stage product development entities.

財務健全性

The company reported a total revenue of $105.97 million over the trailing twelve months, yet this revenue generated a net income of $-81,130,000, revealing a cost structure where operating expenses and R&D investments significantly outweigh current earnings before tax. The EBITDA for the same period stands at $-84,824,000, further illustrating that the business model currently requires substantial cash outflow to sustain operations and advance its proprietary drug conjugate and Azymetric multispecific antibody platforms. Free cash flow for the trailing twelve months was $-12,959,125, which indicates that the company is burning cash and relies on external financing or existing reserves to fund its growth initiatives rather than generating internal liquidity. The gross margin is listed at -29.3%, while the operating margin reaches -1755.5% and the profit margin is -76.6%; these deeply negative figures reflect the heavy expense load inherent in developing novel therapeutics before generating significant commercial revenue. In terms of liquidity and leverage, the company holds $228.80 million in cash against $18.27 million in debt, resulting in a debt-to-equity ratio of 6.80, which suggests a leveraged balance sheet structure common for biotechs that prioritize R&D over debt reduction. Despite the leverage, the current ratio of 5.88 indicates a robust short-term liquidity position, providing ample coverage for current liabilities. Finally, the return on equity is -26.7% and the return on assets is -14.3%, metrics that reveal that, at this stage of development, management effectiveness is measured by the preservation of capital and the successful advancement of clinical programs rather than the generation of shareholder returns.

バリュエーション評価

Zymeworks Inc. reports a P/E ratio (TTM) as N/A due to negative earnings, while the forward P/E is 33.93; this divergence implies that the market is pricing in anticipated future profitability that does not yet exist in current financial statements. The price to book ratio stands at 7.43, indicating that the market values the company's equity at a significant premium over its accounting book value, a typical valuation for firms with high intangible assets like intellectual property. Alternative valuation metrics such as the price to sales ratio of 18.73 and the EV/EBITDA of -20.74 suggest that investors are valuing the company primarily based on revenue potential and future growth prospects rather than current profitability or cash flow generation. Regarding trading range, the 52-week high was $28.49 and the 52-week low was $9.03, meaning the current trading price sits between these extremes, reflecting ongoing market volatility and sentiment shifts regarding the company's pipeline progress. The stock exhibits a beta of 1.20, which signifies that the share price is expected to be 20% more volatile than the broader market index, exposing investors to higher systematic risk in exchange for potential upside if the biotechnology sector outperforms.

Growth & Income

The company's revenue growth year-over-year is -91.9%, while earnings growth is N/A due to the lack of positive earnings; this contraction in revenue suggests a decline in sales or a shift in the product mix, while the absence of earnings growth is a direct consequence of the company's current loss-making status. Zymeworks does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the company retains all available cash to reinvest into research and development, clinical trials, and operational expansion rather than distributing income to shareholders. Consequently, the overall growth and income profile of Zymeworks is characterized by a complete reliance on capital appreciation and the successful commercialization of its biotherapeutic platforms, with no current mechanism for income generation via dividends. This reinvestment strategy is standard for biotechnology firms attempting to navigate the long and expensive path to bringing new drugs to market.